Safety of Sofosbuvir and Daclatasvir in Patients having Ischemic Heart Disease for Treatment of HCV Compensated Cirrhosis

Autor:	Ahmed Rezq
Rok vydání:	2020
Předmět:	medicine.medical_specialty Cirrhosis Daclatasvir Sofosbuvir business.industry Disease medicine.disease Gastroenterology Internal medicine medicine General Earth and Planetary Sciences In patient business Ischemic heart General Environmental Science medicine.drug
Zdroj:	American Journal of Biomedical Science & Research. 9:340-345
ISSN:	2642-1747
DOI:	10.34297/ajbsr.2020.09.001420
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b1999aff08458aee0108ee014e33210d https://doi.org/10.34297/ajbsr.2020.09.001420 Zobrazit plný text záznamu